Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation

Mehdi Hamadani, Craig C. Hofmeister, Buffy Jansak, Gary Phillips, Patrick Elder, William Blum, Sam Penza, Thomas S. Lin, Rebecca Klisovic, Guido Marcucci, Sherif Farag, Steven M. Devine

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Infliximab, a chimeric monoclonal antibody (mAb) against tumor necrosis factor (TNF)-α, has shown activity against steroid refractory acute graft-versus-host disease (aGVHD). We conducted a prospective trial of infliximab for the prophylaxis of aGVHD. Patients older than 20 years undergoing myeloablative allogeneic stem cell transplantation (SCT) for hematologic malignancies were eligible. GVHD prophylaxis consisted of infliximab given 1 day prior to conditioning and then on days 0, +7, +14, +28, and +42, together with standard cyclosporine (CSA) and methotrexate (MTX). Nineteen patients with a median age of 53 years were enrolled. All patients received peripheral blood allografts from matched sibling (n = 14) or unrelated donors (n = 5). Results were compared with a matched historic control group (n = 30) treated contemporaneously at our institution. The cumulative incidences of grades II-IV aGVHD in the infliximab and control groups were 36.8% and 36.6%, respectively (P = .77). Rates of chronic GVHD were 78% and 61%, respectively (P = .22). Significantly more bacterial and invasive fungal infections were observed in the infliximab group (P = .01 and P = .02, respectively). Kaplan-Meier estimates of 2-year overall survival (OS) and progression free survival (PFS) for patients receiving infliximab were 42% and 36%, respectively. The corresponding numbers for patients in the control group were 46% and 43%, respectively. The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections.

Original languageEnglish
Pages (from-to)783-789
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume14
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Cell Transplantation
Graft vs Host Disease
Blood Cells
Control Groups
Unrelated Donors
Kaplan-Meier Estimate
Stem Cell Transplantation
Hematologic Neoplasms
Infliximab
Methotrexate
Cyclosporine
Disease-Free Survival
Allografts
Siblings
Tumor Necrosis Factor-alpha
Steroids
Monoclonal Antibodies
Survival
Incidence

Keywords

  • Allogeneic
  • Graft-versus-host disease
  • Hematopoitic stem cell transplantation
  • Infliximab
  • Steroid refractory
  • Tumor necrosis factor
  • Unrelated donor

ASJC Scopus subject areas

  • Transplantation

Cite this

Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation. / Hamadani, Mehdi; Hofmeister, Craig C.; Jansak, Buffy; Phillips, Gary; Elder, Patrick; Blum, William; Penza, Sam; Lin, Thomas S.; Klisovic, Rebecca; Marcucci, Guido; Farag, Sherif; Devine, Steven M.

In: Biology of Blood and Marrow Transplantation, Vol. 14, No. 7, 07.2008, p. 783-789.

Research output: Contribution to journalArticle

Hamadani, M, Hofmeister, CC, Jansak, B, Phillips, G, Elder, P, Blum, W, Penza, S, Lin, TS, Klisovic, R, Marcucci, G, Farag, S & Devine, SM 2008, 'Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 14, no. 7, pp. 783-789. https://doi.org/10.1016/j.bbmt.2008.04.006
Hamadani, Mehdi ; Hofmeister, Craig C. ; Jansak, Buffy ; Phillips, Gary ; Elder, Patrick ; Blum, William ; Penza, Sam ; Lin, Thomas S. ; Klisovic, Rebecca ; Marcucci, Guido ; Farag, Sherif ; Devine, Steven M. / Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2008 ; Vol. 14, No. 7. pp. 783-789.
@article{6b7fdd45a6e042c594c407c5cdb171a7,
title = "Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation",
abstract = "Infliximab, a chimeric monoclonal antibody (mAb) against tumor necrosis factor (TNF)-α, has shown activity against steroid refractory acute graft-versus-host disease (aGVHD). We conducted a prospective trial of infliximab for the prophylaxis of aGVHD. Patients older than 20 years undergoing myeloablative allogeneic stem cell transplantation (SCT) for hematologic malignancies were eligible. GVHD prophylaxis consisted of infliximab given 1 day prior to conditioning and then on days 0, +7, +14, +28, and +42, together with standard cyclosporine (CSA) and methotrexate (MTX). Nineteen patients with a median age of 53 years were enrolled. All patients received peripheral blood allografts from matched sibling (n = 14) or unrelated donors (n = 5). Results were compared with a matched historic control group (n = 30) treated contemporaneously at our institution. The cumulative incidences of grades II-IV aGVHD in the infliximab and control groups were 36.8{\%} and 36.6{\%}, respectively (P = .77). Rates of chronic GVHD were 78{\%} and 61{\%}, respectively (P = .22). Significantly more bacterial and invasive fungal infections were observed in the infliximab group (P = .01 and P = .02, respectively). Kaplan-Meier estimates of 2-year overall survival (OS) and progression free survival (PFS) for patients receiving infliximab were 42{\%} and 36{\%}, respectively. The corresponding numbers for patients in the control group were 46{\%} and 43{\%}, respectively. The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections.",
keywords = "Allogeneic, Graft-versus-host disease, Hematopoitic stem cell transplantation, Infliximab, Steroid refractory, Tumor necrosis factor, Unrelated donor",
author = "Mehdi Hamadani and Hofmeister, {Craig C.} and Buffy Jansak and Gary Phillips and Patrick Elder and William Blum and Sam Penza and Lin, {Thomas S.} and Rebecca Klisovic and Guido Marcucci and Sherif Farag and Devine, {Steven M.}",
year = "2008",
month = "7",
doi = "10.1016/j.bbmt.2008.04.006",
language = "English",
volume = "14",
pages = "783--789",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation

AU - Hamadani, Mehdi

AU - Hofmeister, Craig C.

AU - Jansak, Buffy

AU - Phillips, Gary

AU - Elder, Patrick

AU - Blum, William

AU - Penza, Sam

AU - Lin, Thomas S.

AU - Klisovic, Rebecca

AU - Marcucci, Guido

AU - Farag, Sherif

AU - Devine, Steven M.

PY - 2008/7

Y1 - 2008/7

N2 - Infliximab, a chimeric monoclonal antibody (mAb) against tumor necrosis factor (TNF)-α, has shown activity against steroid refractory acute graft-versus-host disease (aGVHD). We conducted a prospective trial of infliximab for the prophylaxis of aGVHD. Patients older than 20 years undergoing myeloablative allogeneic stem cell transplantation (SCT) for hematologic malignancies were eligible. GVHD prophylaxis consisted of infliximab given 1 day prior to conditioning and then on days 0, +7, +14, +28, and +42, together with standard cyclosporine (CSA) and methotrexate (MTX). Nineteen patients with a median age of 53 years were enrolled. All patients received peripheral blood allografts from matched sibling (n = 14) or unrelated donors (n = 5). Results were compared with a matched historic control group (n = 30) treated contemporaneously at our institution. The cumulative incidences of grades II-IV aGVHD in the infliximab and control groups were 36.8% and 36.6%, respectively (P = .77). Rates of chronic GVHD were 78% and 61%, respectively (P = .22). Significantly more bacterial and invasive fungal infections were observed in the infliximab group (P = .01 and P = .02, respectively). Kaplan-Meier estimates of 2-year overall survival (OS) and progression free survival (PFS) for patients receiving infliximab were 42% and 36%, respectively. The corresponding numbers for patients in the control group were 46% and 43%, respectively. The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections.

AB - Infliximab, a chimeric monoclonal antibody (mAb) against tumor necrosis factor (TNF)-α, has shown activity against steroid refractory acute graft-versus-host disease (aGVHD). We conducted a prospective trial of infliximab for the prophylaxis of aGVHD. Patients older than 20 years undergoing myeloablative allogeneic stem cell transplantation (SCT) for hematologic malignancies were eligible. GVHD prophylaxis consisted of infliximab given 1 day prior to conditioning and then on days 0, +7, +14, +28, and +42, together with standard cyclosporine (CSA) and methotrexate (MTX). Nineteen patients with a median age of 53 years were enrolled. All patients received peripheral blood allografts from matched sibling (n = 14) or unrelated donors (n = 5). Results were compared with a matched historic control group (n = 30) treated contemporaneously at our institution. The cumulative incidences of grades II-IV aGVHD in the infliximab and control groups were 36.8% and 36.6%, respectively (P = .77). Rates of chronic GVHD were 78% and 61%, respectively (P = .22). Significantly more bacterial and invasive fungal infections were observed in the infliximab group (P = .01 and P = .02, respectively). Kaplan-Meier estimates of 2-year overall survival (OS) and progression free survival (PFS) for patients receiving infliximab were 42% and 36%, respectively. The corresponding numbers for patients in the control group were 46% and 43%, respectively. The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections.

KW - Allogeneic

KW - Graft-versus-host disease

KW - Hematopoitic stem cell transplantation

KW - Infliximab

KW - Steroid refractory

KW - Tumor necrosis factor

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=44649176508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649176508&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2008.04.006

DO - 10.1016/j.bbmt.2008.04.006

M3 - Article

VL - 14

SP - 783

EP - 789

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -